版本:
中国

BRIEF-Acorda to discontinue development of Dalfampridine for treatment of post-stroke walking difficulties

Nov 21 Acorda Therapeutics Inc -

* Milestone clinical study did not show sufficient efficacy to support further development of dalfampridine to improve pswd

* To discontinue development of dalfampridine for treatment of post-stroke walking difficulties

* Plan to focus research and development resources on developing our promising late-stage parkinson's disease therapies, CVT-301 and tozadenant

* Also plan to focus research and development resources on advancing earlier stage assets, CVT-427 in migraine, SYN120 in parkinson's disease dementia, rHIgM22 in MS Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐